The role of FSH and TSH in bone loss and its clinical relevance

被引：17
作者：
Agrawal M. [1 ]
Zhu G. [1 ]
Sun L. [1 ]
Zaidi M. [1 ]
Iqbal J. [1 ]
机构：
[1] Mount Sinai Bone Program, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, One Gustave Levy Place
来源：
Current Osteoporosis Reports | 2010年 / 8卷 / 4期
基金：
美国国家卫生研究院;
关键词：
Bone loss; Estrogen; FSH; Menopause; Osteoclast; Osteoporosis; TSH;
D O I：
10.1007/s11914-010-0028-x
中图分类号：
学科分类号：
摘要：
Osteoporosis, a global health problem, is now frequently recognized to be secondary to alterations in the pituitary-bone axis. This review examines the current evidence for how dysregulation of the pituitary-bone axis leads to osteoporotic bone loss. Specifically, perimenopausal bone loss in the context of follicle-stimulating hormone action, and hyperthyroid bone loss in the context of thyroid-stimulating hormone action are explored. From the reviewed scientific findings, recommendations for early diagnosis and better clinical management of bone loss are made. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：205 / 211
页数：6
相关论文
共 65 条
[1]  
Sun L., Peng Y., Sharrow A.C., Et al., FSH directly regulates bone mass, Cell, 125, pp. 247-260, (2006)
[2]  
Sowers M.R., Finkelstein J.S., Ettinger B., Bondarenko I., Neer R.M., Cauley J.A., Sherman S., Greendale G.A., The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN, Osteoporosis International, 14, 1, pp. 44-52, (2003)
[3]  
Akhter M.P., Lappe J.M., Davies K.M., Recker R.R., Transmenopausal changes in the trabecular bone structure, Bone, 41, 1, pp. 111-116, (2007)
[4]  
Recker R., Lappe J., Davies K.M., Heaney R., Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients, Journal of Bone and Mineral Research, 19, 10, pp. 1628-1633, (2004)
[5]  
Ross D.S., Hyperthyroidism, thyroid hormone therapy, and bone, Thyroid, 4, pp. 319-326, (1994)
[6]  
Baran D.T., Thyroid hormone and bone mass: The clinician's dilemma, Thyroid, 4, pp. 143-144, (1994)
[7]  
Abe E., Marians R.C., Yu W., Wu X.-B., Ando T., Li Y., Iqbal J., Eldeiry L., Rajendren G., Blair H.C., Davies T.F., Zaidi M., TSH is a negative regulator of skeletal remodeling, Cell, 115, 2, pp. 151-162, (2003)
[8]  
Imam A., Iqbal J., Blair H.C., Et al., Role of the pituitary-bone axis in skeletal pathophysiology, Curr Opin Endocrinol Diabetes Obes, 16, pp. 423-429, (2009)
[9]  
Wu Y., Torchia J., Yao W., Et al., Bone microenvironment specific roles of ITAM adapter signaling during bone remodeling induced by acute estrogen-deficiency, PLoS One, 2, (2007)
[10]  
Gao J., Tiwari-Pandey R., Samadfam R., Yang Y., Miao D., Karaplis A.C., Sairam M.R., Goltzman D., Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone, Endocrinology, 148, 6, pp. 2613-2621, (2007)
1234567